INTRODUCTION: The aim of this analysis was to examine the performance of the Myasthenia Gravis-specific Activities of Daily Living scale (MG-ADL) during a multicenter scale validation study. METHODS: Consecutive MG patients were assessed with several MG outcome measures, including the MG-ADL. Statistical tests included descriptive analysis, Pearson correlation, and sensitivity/specificity. RESULTS: Eighty-seven patients completed the MG-ADL, MG Composite (MGC), and MG 15-item Quality of Life scale (MG-QOL15) on the first visit, and 76 returned for the second visit. At the first visit, there was a strong positive correlation between MG-ADL and MGC (r = 0.85, P < 0.0001) and MG-QOL15 (r = 0.76, P < 0.0001). Correlation of the delta MG-ADL score and physician impression of change between the visits was strong (r = 0.70, P < 0.0001). A 2-point improvement in the MG-ADL best predicted clinical improvement. Test-retest analysis demonstrated a high reliability coefficient. CONCLUSIONS: The MG-ADL correlates strongly with newer, validated MG outcome measures. A 2-point improvement in the MG-ADL indicates clinical improvement. The MG-ADL is useful as a research tool and in routine clinical management.
INTRODUCTION: The aim of this analysis was to examine the performance of the Myasthenia Gravis-specific Activities of Daily Living scale (MG-ADL) during a multicenter scale validation study. METHODS: Consecutive MGpatients were assessed with several MG outcome measures, including the MG-ADL. Statistical tests included descriptive analysis, Pearson correlation, and sensitivity/specificity. RESULTS: Eighty-seven patients completed the MG-ADL, MG Composite (MGC), and MG 15-item Quality of Life scale (MG-QOL15) on the first visit, and 76 returned for the second visit. At the first visit, there was a strong positive correlation between MG-ADL and MGC (r = 0.85, P < 0.0001) and MG-QOL15 (r = 0.76, P < 0.0001). Correlation of the delta MG-ADL score and physician impression of change between the visits was strong (r = 0.70, P < 0.0001). A 2-point improvement in the MG-ADL best predicted clinical improvement. Test-retest analysis demonstrated a high reliability coefficient. CONCLUSIONS: The MG-ADL correlates strongly with newer, validated MG outcome measures. A 2-point improvement in the MG-ADL indicates clinical improvement. The MG-ADL is useful as a research tool and in routine clinical management.
Authors: James F Howard; Vera Bril; Ted M Burns; Renato Mantegazza; Malgorzata Bilinska; Andrzej Szczudlik; Said Beydoun; Francisco Javier Rodriguez De Rivera Garrido; Fredrik Piehl; Mariarosa Rottoli; Philip Van Damme; Tuan Vu; Amelia Evoli; Miriam Freimer; Tahseen Mozaffar; E Sally Ward; Torsten Dreier; Peter Ulrichts; Katrien Verschueren; Antonio Guglietta; Hans de Haard; Nicolas Leupin; Jan J G M Verschuuren Journal: Neurology Date: 2019-05-22 Impact factor: 9.910
Authors: Gil I Wolfe; Henry J Kaminski; Inmaculada B Aban; Greg Minisman; Hui-Chien Kuo; Alexander Marx; Philipp Ströbel; Claudio Mazia; Joel Oger; J Gabriel Cea; Jeannine M Heckmann; Amelia Evoli; Wilfred Nix; Emma Ciafaloni; Giovanni Antonini; Rawiphan Witoonpanich; John O King; Said R Beydoun; Colin H Chalk; Alexandru C Barboi; Anthony A Amato; Aziz I Shaibani; Bashar Katirji; Bryan R F Lecky; Camilla Buckley; Angela Vincent; Elza Dias-Tosta; Hiroaki Yoshikawa; Márcia Waddington-Cruz; Michael T Pulley; Michael H Rivner; Anna Kostera-Pruszczyk; Robert M Pascuzzi; Carlayne E Jackson; Guillermo S Garcia Ramos; Jan J G M Verschuuren; Janice M Massey; John T Kissel; Lineu C Werneck; Michael Benatar; Richard J Barohn; Rup Tandan; Tahseen Mozaffar; Robin Conwit; Joanne Odenkirchen; Joshua R Sonett; Alfred Jaretzki; John Newsom-Davis; Gary R Cutter Journal: N Engl J Med Date: 2016-08-11 Impact factor: 91.245